Benjamin Lockshin, MD, FAAD, the director of the Clinical Trials Center at U.S. Dermatology Partners, discusses using bimekizumab (Bimzelx) for the treatment of moderate-to-severe psoriasis and psoriatic arthritis. In the BE READY trial (NCT03410992), bimekizumab demonstrated the ability to achieve high levels of skin clearance, with 80% mean improvement in 4 weeks and complete clearance in 16 weeks, faster than other biologics. Dr. Lockshin notes that in clinical practice, it has also shown to be effective in both biologic-naive and previously treated patients. Additionally, bimekizumab offers significant joint control and improves patients’ quality of life, making it a versatile option for managing psoriatic disease, according to Dr. Lockshin. Adverse events with bimekizumab included oral and esophageal candidiasis, liver function test abnormalities, with their rates consistent with both active comparator groups in the trials.   Topics Covered: Achieving complete clearance with bimekizumab Dosing and treatment response Adverse effects and safety profile   Explore Related Resources: Case Series: Successful Management of Refractory Plaque Psoriasis With Combined Laser Therapy and Topical Roflumilast in 2 Patients The Treatment of Perioral (Periorificial) Dermatitis With Topical Roflumilast 0.3% Cream: An Illustrative Case Study With Rapid Onset and Prolonged Remission